Daniel Bryan Tracey

US Patent:

20130058943, Mar 7, 2013

Filed:

Aug 1, 2012

Appl. No.:

13/564566

Inventors:

Barbara S. Fox - Wayland MA, US
Eileen F. Bostwick - Waltham MA, US
Daniel E. Tracey - Harvard MA, US
Lisa D. Schlehuber - Arlington MA, US
Michael S. Quesenberry - Douglas MA, US

International Classification:

C07K 16/24
C07K 1/36
A61P 1/00
A61K 39/395
A61P 29/00

US Classification:

4241391, 5303892, 5303879, 4241581, 4241571

Abstract:

The invention provides a composition comprising polyclonal antibodies that specifically bind to with human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized hTNF or an immunogenic portion thereof. The antigenic specificity analysis of the anti-hTNF polyclonal antibodies of the invention is unique and has not been previously described for anti-hTNF polyclonal or monoclonal antibodies of the prior art.

US Patent:

60544872, Apr 25, 2000

Filed:

Mar 18, 1997

Appl. No.:

8/820692

Inventors:

Les Sekut - Westborough MA
Adam Carter - Newburyport MA
Tariq Ghayur - Grafton MA
Subhashis Banerjee - Shrewsbury MA
Daniel E. Tracey - Harvard MA

Assignee:

BASF Aktiengesellschaft - Rheinland Pfalz

International Classification:

A61K 3118

US Classification:

514604

Abstract:

Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-. gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-. gamma. inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists.

US Patent:

20150368335, Dec 24, 2015

Filed:

Sep 3, 2015

Appl. No.:

14/844578

Inventors:

- Hamilton, BM
Lori K. Taylor - Boston MA, US
Clive E. Spiegler - Skillman NJ, US
Daniel E. Tracey - Harvard MA, US
Elliot K. Chartash - Marietta GA, US
Rebecca S. Hoffman - Wilmette IL, US
William T. Barchuk - San Diego CA, US
Philip Yan - Vernon Hills IL, US
Anwar Murtaza - Westborough MA, US
Jochen G. Salfeld - North Grafton MA, US
Steven A. Fischkoff - Short Hills NJ, US

International Classification:

C07K 16/24
A61K 39/395

Abstract:

Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described.

US Patent:

20150037348, Feb 5, 2015

Filed:

Jul 10, 2014

Appl. No.:

14/328439

Inventors:

- Wiesbaden, DE
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warner - Andover MA, US
Angela Myles - Pepperell MA, US
John Gawain Elvin - Royston, GB
Alexander Robert Duncan - Cambridge, GB
Elaine Joy Derbyshire - Berks, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Ronde, DK
Sarah Du Fou - Hitchen, GB

International Classification:

C07K 16/24
A61K 47/26
A61K 47/20
A61K 9/00
A61K 47/22

US Classification:

4241581

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.